Abstract
Objective Istradefylline, a selective adenosine A2A receptor antagonist, is indicated in the US and Japan as adjunctive treatment to levodopa/decarboxylase inhibitors in adults with Parkinson’s disease (PD) experiencing OFF time. This study aimed to observe patterns of dose escalation of levodopa over time in patients initiated on istradefylline.
Methods Using Japanese electronic health record data, interrupted time series analyses were used to compare levodopa daily dose (LDD, mg/day) gradients in patients before and after initiation of istradefylline. Data were analyzed by period relative to istradefylline initiation (Month 1): pre-istradefylline (Months -72 to 0), early istradefylline (Months 1 to 24), and late istradefylline (Months 25 to 72). Subgroup analyses included LDD before istradefylline initiation (<400, ≥400 to <600, ≥600 mg/day) and treatment with or without monoamine oxidase-B inhibitors (MAO-BIs), catechol-O-methyltransferase inhibitors (COMTIs), or dopamine agonists before istradefylline initiation.
Results The analysis included 4026 patients; mean (SD) baseline LDD was 419.27 mg (174.19). Patients receiving ≥600 mg/day levodopa or not receiving MAO-BIs or COMTIs demonstrated a significant reduction in LDD increase gradient for pre-istradefylline vs late-phase istradefylline (≥600 mg/day levodopa, -6.259 mg/day each month, p<0.001; no MAO-BIs, -1.819 mg/day each month, p=0.004; no COMTIs, -1.412 mg/day each month, p=0.027).
Conclusions This real-world analysis of Japanese prescription data indicated that slowing of LDD escalation was observed in patients initiated on istradefylline, particularly in those receiving ≥600 mg/day levodopa, suggesting istradefylline may slow progressive LDD increases. These findings suggest that initiating istradefylline before other levodopa-adjunctive therapies may mitigate LDD increases, potentially reducing occurrence or severity of levodopa-induced complications in long-term istradefylline treatment.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: NH: Research funding from AbbVie, Asahi Kasei Medical, Astellas, Boston Scientific, Daiichi Sankyo, Dai-Nippon Sumitomo, Eisai, FP Pharmaceutical, Kyowa Kirin, Medtronic, Mitsubishi Tanabe, MiZ, Nihon Medi-Physics, Nihon Pharmaceutical, Nippon Boehringer Ingelheim, OHARA, Ono Pharmaceutical, Otsuka, Takeda consulting for Dai-Nippon Sumitomo advisory boards for Dai-Nippon Sumitomo, Kyowa Kirin, Otsuka, Sanofi, Takeda subcontracting (trial cases) for Biogen Japan, Hisamitsu, Meiji Seika contract research for Biogen Japan, Mitsubishi Tanabe honoraria from AbbVie, Alexion, Boston Scientific, Daiichi Sankyo, Dai-Nippon Sumitomo, FP Pharmaceutical, Kyowa Kirin, Lundbeck Japan, Medtronic, MSD K.K., Mylan, Nippon Boehringer Ingelheim, Novartis, Otsuka, Pfizer Japan, Takeda. DK: Honoraria for statistical analysis, consulting, and lecturing from Kyowa Kirin Co., Ltd. SA, TK, TN & AM: Employment with Kyowa Kirin Co., Ltd. AS: Honoraria for statistical analysis, consulting, and lecturing from Kyowa Kirin Co., Ltd.
Funding Statement
This study was funded by Kyowa Kirin, Co., Ltd. (Tokyo, Japan). Kyowa Kirin, Co., Ltd. consulted with advisors and study investigators on the design of this study, provided financial and material support for the study, and, with the assistance of study investigators, monitored the conduct of the study, collected data, and analyzed the data. SA, TK, TN, AS, and AM, who are all employees of Kyowa Kirin Co., Ltd., are authors of this manuscript and as such were involved in the interpretation of the data and in the drafting and revision of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis did not require active enrollment, follow-up, or direct contact with patients. Therefore, institutional review board approval and written informed consent were not required for the conduct of this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
The data used for the analyses in this manuscript are available on request from the corresponding author.
